Details of the Drug Combination

General Information of Drug Combination (ID: DC53K6M)

• Drug Combination Name: BIO-300 + Valproic Acid
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  BIO-300 (DMJ7NVI): N.A.
  Valproic Acid (DMS49KH): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 2.63
  Bliss Independence Score: 2.63
  Loewe Additivity Score: 2.99
  LHighest Single Agent (HSA) Score: 2.99

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Clinical pipeline report, company report or official report of Humanetics.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Valproic Acid FDA Label
• [5] Immunopharmacological management of COVID-19: Potential therapeutic role of valproic acid. Med Hypotheses. 2020 May 27;143:109891.